Table 3 CHD events in women taking... | American Society of Hematology

Table 3

CHD events in women taking placebo according to GP1BA and GP6 polymorphisms

	n	Year 1				End of follow-up
	n	Cases, n	Rate*	HR (CI)†	P†	Cases, n	Rate*	HR (CI)†	P†
GP1BA −5T>C					.085				.006
TT	789	32	41.3	1.00		186	40.37	1.00	—
TC	233	15	66.5	1.64 (0.88-3.05)		68	51.52	1.27 (0.96-1.68)	—
CC	25	2	84.1	2.03 (0.47-8.65)		12	107.42	2.25 (1.25-4.06)	—
GP6 13254T>C					.146				.20
TT	725	38	53.8	1.00		193	46.47	1.00	—
TC	289	10	35.17	0.58 (0.28-1.2)		65	38.48	0.82 (0.62-1.09)	—
CC	33	1	30.57	0.74 (0.27-2.0)		8	40.69	0.91 (0.64-1.3)	—

	n	Year 1				End of follow-up
	n	Cases, n	Rate*	HR (CI)†	P†	Cases, n	Rate*	HR (CI)†	P†
GP1BA −5T>C					.085				.006
TT	789	32	41.3	1.00		186	40.37	1.00	—
TC	233	15	66.5	1.64 (0.88-3.05)		68	51.52	1.27 (0.96-1.68)	—
CC	25	2	84.1	2.03 (0.47-8.65)		12	107.42	2.25 (1.25-4.06)	—
GP6 13254T>C					.146				.20
TT	725	38	53.8	1.00		193	46.47	1.00	—
TC	289	10	35.17	0.58 (0.28-1.2)		65	38.48	0.82 (0.62-1.09)	—
CC	33	1	30.57	0.74 (0.27-2.0)		8	40.69	0.91 (0.64-1.3)	—

— indicates not applicable.

Expressed as n/1000/y.

Additive model adjusted for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, aspirin use, and statin use at baseline.